W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

News

01 June, 2022

Communication on – data acquisition – Respiratory diseases

01 June, 2022

Recommendation of the President – PET/MRI

01 June, 2022

Recommendation of the President – PET/MRI

01 June, 2022

Recommendation of the President – PET/MRI

31 May, 2022

Recommendation of the President – Tysabri (natalizumab)

31 May, 2022

Recommendation of the President – Tysabri (natalizumab)

30 May, 2022

Recommendation of the President – Olumiant (baricytynib)

26 May, 2022

Communication on the meeting of the Tariffs Council on 24 May 2022

18 May, 2022

Opinion of the Transparency Council – carbamazepine

21 June, 2022

The Meeting of the Transparency Council No. 25/2022 of 27.06.2022

20 June, 2022

The Meeting of the Tariffs Council No. 14/2022 of 24.06.2022

20 June, 2022

The Meeting of the Tariffs Council No. 13/2022 of 23.06.2022

14 June, 2022

The Meeting of the Transparency Council No. 24/2022 of 20.06.2022

06 June, 2022

Position of the Transparency Council – Dupixent (dupilumabum)

06 June, 2022

Opinion of the Transparency Council – “Programme of early detection of colorectal cancer among residents of the town of Krosno for 2022-2023”.

06 June, 2022

Opinion of the Transparency Council – “Programme of early detection of breast cancer among female residents of the town of Krosno for 2022-2023”.

03 June, 2022

The Meeting of the Tariffs Council No. 14/2022 of 09.06.2022

01 June, 2022

Position of the Transparency Council – Lynparza (olaparibum)

01 June, 2022

Position of the Transparency Council – Betaquik

01 June, 2022

Opinion of the Transparency Council – Programme for prevention and early detection of overweight and obesity among children from classes IV-VIII, pupils of primary schools from the Radom Poviat area, for 2022-2023″,,

01 June, 2022

Opinion of the Transparency Council – “Health programme of secondary prevention of cervical cancer self-sampling – screening based on HPV test” ( (Kobierzyce municipality).

30 May, 2022

The Meeting of the Transparency Council No. 22/2022 of 06.06.2022

26 May, 2022

Position of the Transparency Council – Xtandi (enzalutamidum)

26 May, 2022

Position of the Transparency Council – Doptelet (avatrombopag)

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy